Last mentioned: Mar 14, 2026
Insider Selling
President and another insider report share sales in regulatory filings.
Insider Selling
President and another insider sell a combined 33,157 shares.
Analyst Downgrade
Wall Street Zen cuts ALHC rating to Hold.
Analyst Downgrade
Wall Street Zen cuts ALHC rating to Hold.
Offering Priced
Secondary offering is priced at $19.46 per share.
Secondary Offering
Company prices 13.2M shares at $19.46 to raise capital.
Secondary Offering Announced
Company announces intent to sell 13.2 million shares to raise capital.
Expected Q4 Earnings Call
Management is anticipated to provide final 2025 figures and formal guidance for the 2026 fiscal year.
Q4 Earnings Report
Alignment Healthcare reports a declining net loss for the fourth quarter of 2025.
Q4 Earnings Report
Alignment Healthcare reports declining losses and operational growth.
Earnings Preview Release
FinancialContent and other market trackers highlight ALHC as a key stock to watch ahead of Q4 reporting.
Baird Model Update
Analysts at Baird set a bullish $59 price target for ALHC, signaling high confidence in the tech-enabled MA model.
Alignment Healthcare's President and another insider divested over 33,000 shares in mid-March, following a massive secondary offering and a rating downgrade. The sales come as the Medicare Advantage provider reports narrowing losses but faces a shift in analyst sentiment from 'Buy' to 'Hold.'
Alignment Healthcare (NASDAQ: ALHC) has reported significant insider selling, including a 29,113-share disposal by its President, shortly after a major secondary offering. These transactions occur as the company navigates a shift in analyst sentiment and a challenging regulatory environment for Medicare Advantage providers.
Wall Street Zen has downgraded both Freshworks (FRSH) and Alignment Healthcare (ALHC) to 'Hold,' signaling a shift in analyst sentiment toward these high-growth tech-enabled platforms. This move reflects broader market caution as SaaS and HealthTech firms face increasing pressure to balance aggressive expansion with sustainable profitability.
Investment research platform Wall Street Zen has lowered its ratings for Alignment Healthcare (ALHC) and Freshworks (FRSH) from 'Buy' to 'Hold.' These downgrades signal a shift in market sentiment toward high-growth, tech-enabled entities as they navigate a more cautious public market environment.
Wall Street Zen has lowered its investment ratings for Alignment Healthcare and Freshworks from Buy to Hold, signaling a shift to a neutral outlook. The downgrades reflect a cautious stance on the Medicare Advantage sector and the competitive SaaS landscape as both companies navigate evolving market dynamics in early 2026.
Wall Street Zen has lowered its rating on Alignment Healthcare (ALHC) to "Hold," reflecting broader caution within the Medicare Advantage sector. The downgrade comes as specialized insurers face tightening margins and regulatory shifts in the federal reimbursement landscape.
A diverse group of companies, including DoubleVerify, Coupang, and NCR Atleos, are set to report Q4 earnings, providing critical data points on digital advertising health and e-commerce resilience. This briefing analyzes the implications for the SaaS and Cloud sectors as enterprise and consumer spending patterns emerge from the final quarter of 2025.
A broad spectrum of mid-to-large cap companies across construction, fintech, and e-commerce are set to report fourth-quarter results, providing a critical pulse check on the 2026 economic outlook. Investors are focused on how these firms navigated late-2025 interest rate volatility and shifting consumer demand.
Alignment Healthcare (ALHC) is set to report its fourth-quarter results, with investors focusing on membership growth and the medical loss ratio (MLR) within its tech-enabled Medicare Advantage platform. As the MA market faces regulatory headwinds, ALHC's ability to maintain clinical outcomes through its proprietary AVA software remains a critical differentiator.